Baudax Bio, Inc.
Baudax Bio, Inc.
Your view on BXRXQ
Overview
What the company does, where it operates, and who runs it.
About Baudax Bio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geraldine A. Henwood
- Headquarters
- 490 Lapp Road, Malvern, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geraldine A. Henwood
- Headquarters
- 490 Lapp Road, Malvern, PA, US
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Baudax Bio, Inc., and the rating behind it. BXRXQ last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Baudax Bio, Inc.. Starting points for Baudax Bio, Inc.: EPS -$177.30, beta -11.87 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Baudax Bio, Inc.. Baudax Bio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Baudax Bio, Inc.. Trailing twelve-month EPS for Baudax Bio, Inc. stands at -$177.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Baudax Bio, Inc.. Baudax Bio, Inc. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Baudax Bio, Inc. valued side by side against its closest peers. Baudax Bio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Baudax Bio, Inc., and how their positions are changing. At a $436 market value, institutional positions materially move Baudax Bio, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Baudax Bio, Inc. executives and directors. Shares of Baudax Bio, Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Baudax Bio, Inc.. Baudax Bio, Inc. is a $436 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Baudax Bio, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Baudax Bio, Inc.. Coverage tracks Baudax Bio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.